Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-100 plus pemetrexed and platinum versus placebo plus pemetrexed and platinum in first-line advanced non-squamous NSCLC
2018-004791-36Phase 3Completed
- Sponsor
- BIOCAD
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Prolgolimab combination arm with Placebo combination arm (2 arms). Primary endpoint: overall survival. Started Jul 2019; status: completed.
02
Drugs
prolgolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-004791-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004791-36.